About Blueberry Therapeutics
Blueberry Therapeutics is a Technology company based in Alderley Edge (United Kingdom) founded in 2011 by Michael John Davies. Developer of OTC and prescription products to treat infectious and inflammatory diseases. It operates in the Technology and Healthcare sectors. Blueberry Therapeutics has raised $23.77 million across 5 funding rounds from investors including Maven Capital Partners, China Medical System and Medical Incubator Japan. The company has 16 employees. Blueberry Therapeutics offers products and services including Nanopolymer Drug Delivery System and Therapy for Onychomycosis. Its focus areas include High Tech, Nanotechnology, Nanoenabled Products and Life Science. Its legal entity is BLUEBERRY THERAPEUTICS LIMITED.
Company details
Blueberry Therapeutics is a modern drug discovery and development company specializing in polymer-drug delivery. Its nanopolymer drug delivery system self-assembles with both small and large molecules (e.g. proteins, peptides, and nucleic acids) and packages them into nanoparticles. These nanoparticles enhance cellular delivery into both mammalian and bacterial cells. It is developing OTC products to treat Onychomycosis (fungal nail infection), tinea pedis (athletes foot), acne, and acute wounds. Also developing prescription peptide therapeutics to treat Atopic Dermatitis, Inflammatory Bowel Disease.
- Headquarters Alderley Edge, United Kingdom
- Employees 16
- Founders Michael John Davies
- SectorsTechnologyHealthcare
- Website blueberrytherapeutics.com
- Social LinkedIn X
- Legal Name Blueberry Therapeutics Limited
- Date of Incorporation 08 Nov, 2011
- Jurisdiction MACCLESFIELD, CHESHIRE, UNITED KINGDOM
- Annual Revenue$615.53 K (USD)as on May 31, 2019
- Net Profit-$3.76 M (USD)-37as on May 31, 2022
- EBITDA-$4.68 M (USD)1as on May 31, 2022
- Total Equity Funding$23.77M (USD)
in 5 rounds
- Latest Funding Round$1.06M (USD), Debt – Conventional
Jun 2021
- InvestorsMaven Capital Partners
& 5 more
- Employee Count16
Products & Services of Blueberry Therapeutics
Blueberry Therapeutics offers a comprehensive portfolio of products and services, including Nanopolymer Drug Delivery System and Therapy for Onychomycosis.
Advanced system for topical drug delivery to treat skin disorders effectively.
Nanomedicine-based treatment for fungal nail infections and related conditions.
Funding Insights of Blueberry Therapeutics
Blueberry Therapeutics has successfully raised a total of $23.77M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $1.06 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $23.77M
- Total Rounds 5
- Last Round Debt – Conventional — $1.06M
- First Round $1.75M
(May 2015)
- Investors Count 6
All 5 funding rounds of Blueberry Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $1.06M | Debt – Conventional | – | – | |
| Jan 2021 | $4.91M | Series B | – | Medical Incubator Japan | |
| Aug 2018 | $12.76M | Series B | – | China Medical System | – |
| May 2016 | $4.35M | Series A | – | – | |
| May 2015 | $1.75M | Seed | – | – | – |
6 investors in total: 5 institutional and 1 angel.
Investors in Blueberry Therapeutics
Blueberry Therapeutics has secured backing from 6 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Maven Capital Partners, China Medical System and Medical Incubator Japan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are targeted for private equity investments. | 2005 | mavencp.com | Birmingham, United Kingdom | |
Investment in innovative healthcare startups is facilitated by this company. | medicalincubatorjapan.com | Japan | ||
Venture capital funds are managed for life sciences and growth businesses. | gmclifesciencesfund.com | Enderby, United Kingdom | ||
Generic formulations including tablets, capsules, liquids, and injectables are manufactured. | 1992 | cms.net.cn | Shenzhen, China | |
Provides contract research for clinical trials in biotech and pharmaceuticals. | 1998 | inclin.com | San Mateo Atenco, Mexico | |
OI Omar Ibrahimi | Angel investor and entrepreneur focused on tech startups in India. | unknown_3c067c7d3c594c22b |
Investor details for Blueberry Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Blueberry Therapeutics
2 people are tracked at Blueberry Therapeutics (2 in leadership); the tracked headcount is 16.
| Name | Role | Group |
|---|---|---|
Michael John Davies | Co-Founder | Leadership |
David Edwards | Pharmaceutical Development Director | Leadership |
Complete people profiles for Blueberry Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Blueberry Therapeutics
3 dated milestones of Blueberry Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Blueberry Therapeutics is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Debt – Conventional, of $1.1M.
Top companies in Nanotechnology
3 companies that operate in the same segment as Blueberry Therapeutics (Nanotechnology) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Technology tools and systems for molecular scale are developed. | 1959 | Abingdon, Oxfordshire, United Kingdom | USD 648.1 M | |||
RNA therapeutics for hematology and cardiovascular diseases are developed. | 1999 | London, England, United Kingdom | USD 559 K | 116 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Blueberry Therapeutics
Complete news archive for Blueberry Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Blueberry Therapeutics
Blueberry Therapeutics was founded in 2011 and raised its 1st funding round 4 years after it was founded.
Blueberry Therapeutics is headquartered in Alderley Edge, United Kingdom. It is registered at Alderley Edge, Cheshire, United Kingdom.
Blueberry Therapeutics is a funded company, having raised a total of $23.77M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1.75M, raised on May 2015.
Blueberry Therapeutics has 16 employees.
Annual revenue of Blueberry Therapeutics is $615.53K as on May 31, 2019.
Blueberry Therapeutics is a modern drug discovery and development company specializing in polymer-drug delivery. Its nanopolymer drug delivery system self-assembles with both small and large molecules (e.g. proteins, peptides, and nucleic acids) and packages them into nanoparticles. These nanoparticles enhance cellular delivery into both mammalian and bacterial cells. It is developing OTC products to treat Onychomycosis (fungal nail infection), tinea pedis (athletes foot), acne, and acute wounds. Also developing prescription peptide therapeutics to treat Atopic Dermatitis, Inflammatory Bowel Disease.
Blueberry Therapeutics offers Nanopolymer Drug Delivery System and Therapy for Onychomycosis.
Blueberry Therapeutics has 6 investors. Key investors include Maven Capital Partners, China Medical System, Medical Incubator Japan, Omar Ibrahimi, and InClin.
Blueberry Therapeutics operates through Blueberry Therapeutics Limited.